ArticleInfluenza and other respiratory viruses2016
The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice.
Article in Influenza and other respiratory viruses, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19.The Journal of clinical investigation · 2023Article
- Experimental Search for New Means of Pathogenetic Therapy COVID-19: Inhibitor of H2-Receptors Famotidine Increases the Effect of Oseltamivir on Survival and Immune Status of Mice Infected by A/PR/8/34 (H1N1).Journal of evolutionary biochemistry and physiology · 2022Article
- Can FDA-Approved Immunomodulatory Drugs be Repurposed/Repositioned to Alleviate Chronic Pain?Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021Review
- Review
- Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Divergent Mast Cell Responses Modulate Antiviral Immunity During Influenza Virus Infection.Frontiers in cellular and infection microbiology · 2021Review
- COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.Frontiers in pharmacology · 2021Article
- Harnessing the Power of Mast Cells in unconventional Immunotherapy Strategies and Vaccine Adjuvants.Cells · 2020Review
- "Cytokine storm", not only in COVID-19 patients. Mini-review.Immunology letters · 2020Review
- Tackling the cytokine storm in COVID-19, challenges and hopes.Life sciences · 2020Review
- Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19.Frontiers in pharmacology · 2020Article
- Pre-Treatment with Zirconia Nanoparticles Reduces Inflammation Induced by the Pathogenic H5N1 Influenza Virus.International journal of nanomedicine · 2020Article
- Influenza A Viruses Replicate Productively in Mouse Mastocytoma Cells (P815) and Trigger Pro-inflammatory Cytokine and Chemokine Production through TLR3 Signaling Pathway.Frontiers in microbiology · 2016Article
- The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice.Influenza and other respiratory viruses · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify the protective role of sodium cromoglycate in mice during influenza virus infection.
designH5N1 virus-infected mice were treated with the mast cell stabilizer sodium cromoglycate (SCG) to investigate its therapeutic effect. SAMPLE: The nose, trachea and lungs from mice were collected.
main outcome measuresVirus replication and host responses were determined by plaque assay, quantitative PCR, immunohistochemistry, and histology.
resultsSCG-treated mice survived better than did PBS-treated mice after H5N1 virus infection. Mild pathological changes with fewer inflammatory cell infiltration and fewer virus antigens were observed in the nose, trachea, and lungs of SCG-treated mice on days 3 and 5 post-infection. However, no significant changes in viral load in the lungs were detected between SCG- and PBS-treated mice. Furthermore, significantly decreased expression of interleukin-6, tumor necrosis factor-a, Toll-like receptor 3, and TIR-domain-containing adapter-inducing interferon-b was detected in the lungs of SCG-treated mice, and no higher expression of interferon-c was detected.
conclusionThese results suggest that SCG has therapeutic roles in H5N1 virus-infected mice by alleviating the inflammatory response rather than inhibition of viral replication in the lungs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.